InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,304.72
(
0.70%
)
US TECH 100
18,313.20
(
0.92%
)
Dow Jones
39,069.59
(
0.01%
)
Brent Oil
81.92
(
0.75%
)
Bitcoin
68,934.42
(
1.49%
)
Post# of 251933
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119688
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: iwfal post# 250812

Monday, 05/06/2024 12:11:24 PM

Monday, May 06, 2024 12:11:24 PM

Post# of 251933
EYPT—(-38%)—misses phase-2 primary_endpoint_in DR:

https://www.globenewswire.com/news-release/2024/05/06/2875682/0/en/EyePoint-Pharmaceuticals-Announces-Topline-Data-from-the-Phase-2-PAVIA-Trial-of-DURAVYU-in-Non-Proliferative-Diabetic-Retinopathy.html

The data demonstrated that DURAVYU has a biologic effect in patients with NPDR with a favorable safety and tolerability profile, however the trial did not meet the pre-specified primary endpoint.

Duravyu, formerly known as EYP-1901, is an implant of the VEGF inhibitor, Vorolanib.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up